2025
Shifting respiratory pathogens: Post-COVID-19 trends in community-acquired infections in underserved communities
Rafei R, Osman M, Barake B, Mallat H, Dabboussi F, Hamze M. Shifting respiratory pathogens: Post-COVID-19 trends in community-acquired infections in underserved communities. PLOS ONE 2025, 20: e0329481. PMID: 40845032, PMCID: PMC12373226, DOI: 10.1371/journal.pone.0329481.Peer-Reviewed Original ResearchConceptsInfluenza ARespiratory infectionsLogistic regression modelsCommunity-acquired acute respiratory infectionsRespiratory pathogensCommunity-acquired infectionsParainfluenza virus infectionEpidemiology of respiratory infectionsRespiratory tract infectionsSARS-CoV-2Multivariate logistic regression modelAcute respiratory infectionsAntimicrobial stewardship strategiesLogistic regression analysisGlobal health burdenTract infectionsHuman rhinovirus/enterovirusMulticenter studyParainfluenza virusNasopharyngeal samplesCo-InfectionVirus infectionPatientsRegression modelsPediatric clinicBest Practices in the Development and Use of Experimental Models of Bacterial Pneumonia: An Official American Thoracic Society Workshop Report
Samarasinghe A, Randell S, Kulkarni H, Weiser J, Quinton L, Dickson R, Mizgerd J, Orihuela C, Parker D, Robinson K, Prince A, Evans S, Kolls J, Lee J, Jeyaseelan S, Torres A, Miller L, Hamilton D, Gómez M, Moore B, Walker R, Barkal L, Hook J, Lau G, Sharma J, Witzenrath M, Dela Cruz C. Best Practices in the Development and Use of Experimental Models of Bacterial Pneumonia: An Official American Thoracic Society Workshop Report. American Journal Of Respiratory Cell And Molecular Biology 2025, 73: 178-199. PMID: 40748059, PMCID: PMC12334885, DOI: 10.1165/rcmb.2025-0322st.Peer-Reviewed Original ResearchConceptsAnimal models of bacterial pneumoniaBacterial pneumoniaAnimal modelsAcute lower respiratory tract infectionLower respiratory tract infectionsGlobal incidenceHospital-acquired pneumoniaRespiratory tract infectionsBacterial lung infectionsExperimental modelAmerican Thoracic Society workshopTract infectionsSignificant morbidityPreclinical modelsLung infectionRespiratory infectious diseasesModel infectionPneumoniaIncidence of respiratory infectious diseasesStages of infectionBacterial diseasesInfectionPneumonia typeNon-animal modelsDiseaseRapid Metagenomic Sequencing (RaMSes) of Bronchoalveolar Lavage Fluid for Diagnosis of Infection in Patients with Hematologic Malignancies and Pulmonary Complications
Hensley M, Sayed K, Haidar G, Wang X, Benos P, Ito S, Im A, Geramita E, Shlomchik W, Methé B, Dela Cruz C, Morris A, Kitsios G. Rapid Metagenomic Sequencing (RaMSes) of Bronchoalveolar Lavage Fluid for Diagnosis of Infection in Patients with Hematologic Malignancies and Pulmonary Complications. CHEST Pulmonary 2025, 100173. DOI: 10.1016/j.chpulm.2025.100173.Peer-Reviewed Original ResearchPulmonary complicationsHematologic malignanciesRespiratory pathogensCulture-independent sequencing approachesDetection of fungal pathogensNon-infectious pulmonary complicationsSuspected lower respiratory tract infectionLower respiratory tract infectionsCulture-independent sequencing methodsRespiratory tract infectionsBronchoalveolar lavage fluidDiagnosis of infectionEmpirical antimicrobialsPCR-based testsTract infectionsFungal pathogensMetagenomic sequencingClinical manifestationsSequencing approachLavage fluidMicrobial communitiesCohort studySequencing methodsPatientsComplicationsBimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
Blauvelt A, Langley R, Lebwohl M, Strober B, Warren R, Puig L, Morita A, Gordon K, Fernandez-Peñas P, Kavanagh S, López Pinto J, Lambert J, Hoepken B, Deherder D, Cross N, Thaçi D. Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. Journal Of The American Academy Of Dermatology 2025, 93: 644-653. PMID: 40286813, DOI: 10.1016/j.jaad.2025.04.038.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsComplete skin clearanceSkin clearanceAdverse eventsRates of treatment-emergent adverse eventsModerate to severe plaque psoriasisOpen-label extension trialModerate to severe psoriasisLong-term treatment optionUpper respiratory tract infectionSevere plaque psoriasisOpen-label extensionPhase 3 trialRespiratory tract infectionsDurability of efficacyOral candidiasisEnd-of-studyPlaque psoriasisSevere psoriasisTract infectionsLong-term managementBimekizumabSafety profileTreatment optionsImprove patient well-beingBimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period
Warren R, Lebwohl M, Thaçi D, Gooderham M, Pinter A, Paul C, Gisondi P, Szilagyi B, White K, Deherder D, Staelens F, Lambert J, Strober B. Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period. British Journal Of Dermatology 2025, 193: 44-55. PMID: 39862230, DOI: 10.1093/bjd/ljaf032.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsOpen-label extensionComplete skin clearanceIL-17APlaque psoriasisSkin clearanceIL-17FRates of treatment-emergent adverse eventsTreatment-emergent adverse event ratesModerate to severe plaque psoriasisOpen-label extension periodSafety of bimekizumabUpper respiratory tract infectionDouble-blind periodSevere plaque psoriasisInterleukin (IL)-17ARespiratory tract infectionsYear of treatmentLong-term resultsInflammatory bowel diseaseMonoclonal IgG1 antibodyOral candidiasisClinical responseMaintenance doseTract infectionsSafety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years
Armstrong A, Lebwohl M, Warren R, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Kisa R, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo M, Scotto J, Banerjee S, Strober B, Thaçi D, Blauvelt A. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years. JAMA Dermatology 2025, 161: 56-66. PMID: 39602111, PMCID: PMC11736510, DOI: 10.1001/jamadermatol.2024.4688.Peer-Reviewed Original ResearchLong-term extension trialsExposure-adjusted incidence ratesSevere plaque psoriasisLong-term extensionModerate to severe plaque psoriasisAdverse eventsPlaque psoriasisDouble-blind phase 3 trialStatic Physician's Global Assessment scoreDiscontinuation due to adverse eventsDay 1Physician Global Assessment scoreIncidence rateEffective long-term treatmentUpper respiratory tract infectionClinical response rateGlobal assessment scorePhase 3 trialRespiratory tract infectionsWeeks of treatmentYear of treatmentLong-term treatmentAdverse cardiovascular eventsLong-term safetyCumulative period
2024
156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis
Kieseier B, Montalban X, Williams M, Airas L, Saini S, Hide M, Sussman G, Nakahara J, Bermel R, Dörner T, Loop B, DeLasHeras V, Willi R, Haemmerle S, Zharkov A, Barbier N, Azmon A, Siegel R, Cenni B, Haddad I, Wiendl H, Maurer M, Giménez-Arnau A, Chitnis T. 156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis. Multiple Sclerosis And Related Disorders 2024, 92: 106117. DOI: 10.1016/j.msard.2024.106117.Peer-Reviewed Original ResearchAdverse eventsSafety profileOral Bruton's tyrosine kinase inhibitorTreatment of relapsing multiple sclerosisBruton tyrosine kinase inhibitorSkin/subcutaneous tissue disordersUpper respiratory tract infectionMultiple sclerosisTyrosine kinase inhibitorsPhase 3 trialRespiratory tract infectionsGrouped adverse eventsIntegrated safety analysisNervous system disordersTreatment discontinuationTract infectionsRemibrutinibTissue disordersKinase inhibitorsSystem disordersOff-target effectsGastrointestinal disordersDoseInfectionPooled dataSevere Clinical Outcomes Due to Human Adenoviral Respiratory Infections in Hospitalized Immunocompetent Adults
Legakis L, Nguyen D, Bandaranayake T. Severe Clinical Outcomes Due to Human Adenoviral Respiratory Infections in Hospitalized Immunocompetent Adults. Infectious Diseases In Clinical Practice 2024, 32: e1412. DOI: 10.1097/ipc.0000000000001412.Peer-Reviewed Original ResearchSevere adenoviral infectionAdenoviral infectionImmunocompetent patientsClinical outcomesSmoking historyPulmonary diseaseRisk factorsSevere diseaseAdenoviral respiratory infectionUpper respiratory tract infectionRespiratory viral panelAbsence of feverAdult immunocompetent patientsExtracorporeal membrane oxygenationRespiratory tract infectionsSevere clinical outcomesChronic obstructive pulmonary diseasePresence of coinfectionObstructive pulmonary diseasePotential risk factorsCritical careImmunocompetent adultsImmunocompromised patientsImmunocompetent hostsTract infectionsEarly-life lower respiratory tract infection (LRTI) and risk of school-age asthma - A population-based cohort study
Myklebust Å, Døllner H, Pape K, Rogne T, Risnes K. Early-life lower respiratory tract infection (LRTI) and risk of school-age asthma - A population-based cohort study. 2024, pa3131. DOI: 10.1183/13993003.congress-2024.pa3131.Peer-Reviewed Original ResearchLower respiratory tract infectionsPopulation-based cohort studySchool-age asthmaRespiratory tract infectionsTract infectionsCohort studyExhaled breath analysis: A promising triage test for tuberculosis in young children
Bijker E, Smith J, Mchembere W, McCarthy K, Oord H, Gerritsen J, Click E, Cain K, Song R. Exhaled breath analysis: A promising triage test for tuberculosis in young children. Tuberculosis 2024, 149: 102566. PMID: 39332067, PMCID: PMC11864270, DOI: 10.1016/j.tube.2024.102566.Peer-Reviewed Original ResearchTriage testPaediatric pulmonary tuberculosisRespiratory tract infectionsSymptoms of tuberculosisDiagnose respiratory tract infectionsCross-sectional studyExpectorated sputumTract infectionsPulmonary tuberculosisPaediatric tuberculosisDiagnostic accuracyBreath testYoung childrenYoung infantsTuberculosisExhaled breath analysisBreathingBreath analysisChildrenTriageExhaled breathSputumInfantsPostinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report
Auld S, Sheshadri A, Alexander-Brett J, Aschner Y, Barczak A, Basil M, Cohen K, Dela Cruz C, McGroder C, Restrepo M, Ridge K, Schnapp L, Traber K, Wunderink R, Zhang D, Ziady A, Attia E, Carter J, Chalmers J, Crothers K, Feldman C, Jones B, Kaminski N, Keane J, Lewinsohn D, Metersky M, Mizgerd J, Morris A, Ramirez J, Samarasinghe A, Staitieh B, Stek C, Sun J, Evans S. Postinfectious Pulmonary Complications: Establishing Research Priorities to Advance the Field: An Official American Thoracic Society Workshop Report. Annals Of The American Thoracic Society 2024, 21: 1219-1237. PMID: 39051991, PMCID: PMC12392397, DOI: 10.1513/annalsats.202406-651st.Peer-Reviewed Original ResearchConceptsPulmonary infectionTreatment of pulmonary infectionsLower respiratory tract infectionsLong-term morbidityRespiratory tract infectionsShort-term outcomesAberrant host responseBurden of morbidityReview potential mechanismsPulmonary complicationsTract infectionsPulmonary pathogensSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Causative pathogenRespiratory syndrome coronavirus 2Therapeutic strategiesSyndrome coronavirus 2Host responseInfectionMorbidityPotential mechanismsCoronavirus 2Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials
Gordon K, Thaçi D, Gooderham M, Okubo Y, Strober B, Peterson L, Deherder D, López Pinto J, Gisondi P. Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s404. DOI: 10.25251/skin.8.supp.404.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsSevere plaque psoriasisOpen-label extensionPlaque psoriasisOral candidiasisPatient yrModerate to severe plaque psoriasisUpper respiratory tract infectionLong-term safety of treatmentRespiratory tract infectionsNext scheduled visitYear of treatmentSafety of treatmentLong-term safetySafety findingsTract infectionsLong-term managementBimekizumabSafety profileAdverse eventsPooled analysisClinical trialsQ8WSafety dataPsoriasisInteractions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review
Besteman S, Bogaert D, Bont L, Mejias A, Ramilo O, Weinberger D, Dagan R. Interactions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review. The Lancet Respiratory Medicine 2024, 12: 915-932. PMID: 38991585, DOI: 10.1016/s2213-2600(24)00148-6.Peer-Reviewed Original ResearchRespiratory syncytial virusChildhood respiratory infectionsRespiratory infectionsSyncytial virusStreptococcus pneumoniaeRespiratory syncytial virus vaccineLower respiratory tract infectionsRespiratory tract infectionsSystematic reviewGlobal health burdenYears of ageRSV hospitalisationTract infectionsPneumococcal vaccineSevere diseaseGlobal morbidityEpidemiological associationMonoclonal antibodiesPathogen-pathogen interactionsPneumococciInfectionHealth burdenPathogenesisHost modulationApproaches to disease preventionClinical outcomes and immunological response to SARS-CoV-2 infection among people living with HIV
Amegashie E, Asamoah P, Ativi L, Adusei-Poku M, Bonney E, Tagoe E, Paintsil E, Torpey K, Quaye O. Clinical outcomes and immunological response to SARS-CoV-2 infection among people living with HIV. Experimental Biology And Medicine 2024, 249: 10059. PMID: 38628843, PMCID: PMC11020089, DOI: 10.3389/ebm.2024.10059.Peer-Reviewed Original ResearchConceptsLevels of inflammatory markersResponse to SARS-CoV-2 infectionClinical outcomesSARS-CoV-2 infectionCo-InfectionInflammatory markersSARS-CoV-2HIV patients co-infectedImmune response to SARS-CoV-2 infectionCD4<sup>+</sup> countInitiation of ARTT cell exhaustionPatients co-infectedSevere outcomesAssociated with severe outcomesStudy assessed risk factorsMono-infected individualsResponse to SARS-CoV-2Respiratory tract infectionsImmunological response to SARS-CoV-2Immunological response to SARS-CoV-2 infectionAfrican American raceChronic kidney diseaseIntensive care unitPositive conversion rateGuide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM) ∗
Miller J, Binnicker M, Campbell S, Carroll K, Chapin K, Gonzalez M, Harrington A, Jerris R, Kehl S, Leal S, Patel R, Pritt B, Richter S, Robinson-Dunn B, Snyder J, Telford S, Theel E, Thomson R, Weinstein M, Yao J. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM) ∗. Clinical Infectious Diseases 2024, ciae104. PMID: 38442248, DOI: 10.1093/cid/ciae104.Peer-Reviewed Original ResearchInfectious Diseases Society of AmericaSoft tissue infectionsTissue infectionsTract infectionsMicrobiology laboratoryCentral nervous system infectionLower respiratory tract infectionsUrinary tract infectionHead and neckInfectious Diseases SocietyNervous system infectionRespiratory tract infectionsTissue parasite infectionsUpper respiratory infectionAmerican Society for MicrobiologyProlonged turnaround timeInfectious diseasesTests to orderGenital infectionIntraabdominal infectionsBloodstream infectionsOcular infectionsDiagnosis of infectious diseasesViral syndromeJoint infectionNovel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis
Murray T, Stanley G, Koff J. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis. Infectious Disease Clinics Of North America 2024, 38: 149-162. PMID: 38280761, DOI: 10.1016/j.idc.2023.12.002.Peer-Reviewed Original ResearchConceptsMultidrug-resistant organismsCystic fibrosis transmembrane conductance regulatorCystic fibrosisBeta-lactam/beta-lactamase combinationDevelopment of inhaled formulationsMethicillin-resistant Staphylococcus aureusTherapeutic approachesMultidrug-resistant organism infectionSystemic adverse eventsMultidrug-resistant infectionsTransmembrane conductance regulatorRespiratory tract infectionsCystic fibrosis patientsGram-negative organismsInnovative therapeutic approachesPulmonary infectionTract infectionsConductance regulatorBurkholderia sp.Multidrug resistanceAdverse eventsTreatment optionsAntibiotic resistanceFibrosis patientsOptimal dose
2023
Development and interobserver reliability of a rating scale for lung ultrasound pathology in lower respiratory tract infection
Baloescu C, Chen A, Schnittke N, Hicks B, Zhu M, Kaili M, Shupp J, Chan D, Malia L, Coneybeare D, Gregory K, Kessler D, Raju B, Moore C. Development and interobserver reliability of a rating scale for lung ultrasound pathology in lower respiratory tract infection. WFUMB Ultrasound Open 2023, 1: 100006. DOI: 10.1016/j.wfumbo.2023.100006.Peer-Reviewed Original ResearchLower respiratory tract infectionsRespiratory tract infectionsIntraclass correlation coefficientTract infectionsUltrasound pathologiesRating ScaleSonographic findingsInter-rater reliabilityExpert consensusPleural line abnormalitiesGood inter-rater reliabilityAverage intraclass correlation coefficientSeverity Rating ScalePleural effusionLung aerationSeverity ScaleFourth subsetInterobserver reliabilityCine clipsInfectionUltrasound expertsScanning protocolPathologyB-linesCOVID-19The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness
Feikin D, Karron R, Saha S, Sparrow E, Srikantiah P, Weinberger D, Zar H. The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness. The Lancet Infectious Diseases 2023, 24: e318-e327. PMID: 38000374, DOI: 10.1016/s1473-3099(23)00568-6.Peer-Reviewed Original ResearchLower respiratory tract infectionsRespiratory syncytial virusRSV diseaseRespiratory illnessSyncytial virusRespiratory diseaseAcute lower respiratory tract infectionPrevention of RSVAcute respiratory illnessRespiratory tract infectionsImportant public health benefitsInappropriate antibiotic useSevere respiratory illnessCause infant mortalityCost-effective interventionPublic health benefitsHealth care systemMaternal vaccinesRecurrent hospitalisationsRSV preventionSecondary pneumoniaTract infectionsMiddle-income countriesLung healthAntibiotic useAlnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
Bar N, Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Otero P, Bermúdez M, Martin T, Santoro A, Yee A, Creignou M, Rodriguez C, Cerchione C, De La Rubia J, Oriol A, Waibel H, Besemer B, Thompson E, Kiesel B, Chen J, Chung A, Boss I, Gaudy A, Li S, Hsu K, Godwin C, Burgess M, San-Miguel J, Costa L. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study. Blood 2023, 142: 2011. DOI: 10.1182/blood-2023-180013.Peer-Reviewed Original ResearchRelapsed/Refractory Multiple MyelomaTreatment-emergent adverse eventsT-cell engagersLines of therapyOverall response ratePhase 1 studyTarget dosesTarget doseMedian PFSData cutoffMedian timeSafety profileCD3 T-cell engagerUpper respiratory tract infectionAnti-CD38 therapyAntitumor activityGrade 1 neurotoxicityTreatment-related deathsCytokine release syndromeRefractory multiple myelomaRespiratory tract infectionsPhase 1 trialPopulation pharmacokinetic analysisHuman clinical studiesObserved trough concentrationsA Diagnostic Approach to Fungal Pneumonia An Infectious Diseases Perspective
Azar M. A Diagnostic Approach to Fungal Pneumonia An Infectious Diseases Perspective. CHEST Journal 2023, 165: 559-572. PMID: 37813181, DOI: 10.1016/j.chest.2023.10.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsFungal pneumoniaAppropriate diagnostic testingClinical syndromeDiagnostic testingLower respiratory tract infectionsNon-resolving pneumoniaRespiratory tract infectionsInfectious diseases perspectiveTract infectionsRadiographic patternsCommon causeEpidemiologic exposuresCorrect diagnosisRisk populationsPneumoniaDiagnostic approachHost factorsDisease perspectiveConstellation of factorsPatientsSyndromeInfectionEpidemiologyIncidenceDiagnosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply